Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23358650)

1.

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd.

Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.

2.

Safety profile of RNAi nanomedicines.

Barros SA, Gollob JA.

Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7. doi: 10.1016/j.addr.2012.06.007. Epub 2012 Jun 22. Review.

PMID:
22732527
3.

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.

Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I.

J Clin Invest. 2009 Mar;119(3):661-73. doi: 10.1172/JCI37515. Epub 2009 Feb 23.

4.

Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.

Kang MR, Yang G, Place RF, Charisse K, Epstein-Barash H, Manoharan M, Li LC.

Cancer Res. 2012 Oct 1;72(19):5069-79. doi: 10.1158/0008-5472.CAN-12-1871. Epub 2012 Aug 6.

5.

Kinesin spindle protein SiRNA slows tumor progression.

Marra E, Palombo F, Ciliberto G, Aurisicchio L.

J Cell Physiol. 2013 Jan;228(1):58-64. doi: 10.1002/jcp.24103.

PMID:
22552964
6.

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD.

Mol Ther. 2014 Jan;22(1):92-101. doi: 10.1038/mt.2013.233. Epub 2013 Oct 3.

7.

Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A.

J Gene Med. 2010 Mar;12(3):287-300. doi: 10.1002/jgm.1431.

PMID:
20052738
8.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
9.

Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA.

Wang J, Ding W, Sun B, Jing R, Huang H, Shi G, Wang H.

Mol Cell Biochem. 2012 Apr;363(1-2):1-10. doi: 10.1007/s11010-011-1151-4. Epub 2011 Dec 15.

PMID:
22170570
10.

A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.

Zhao X, Li DC, Zhao H, Li Z, Wang JX, Zhu DM, Zhou J, Cen JN.

Oncol Rep. 2012 Mar;27(3):628-36. doi: 10.3892/or.2011.1602. Epub 2011 Dec 21.

PMID:
22200682
11.

RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.

Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, Löffler K, Fechtner M, Röhl T, Fisch G, Dames S, Arnold W, Giese K, Klippel A, Kaufmann J.

Gene Ther. 2006 Sep;13(18):1360-70. Epub 2006 Apr 20.

PMID:
16625242
12.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP.

Nature. 2004 Nov 11;432(7014):173-8.

13.

RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.

Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel S, Czubayko F, Aigner A.

Hum Gene Ther. 2006 Jul;17(7):751-66.

PMID:
16839274
14.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

15.

Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.

Han L, Tang C, Yin C.

Biomaterials. 2014 May;35(15):4589-600. doi: 10.1016/j.biomaterials.2014.02.027. Epub 2014 Mar 6.

PMID:
24613049
16.

Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.

DeVincenzo JP.

Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.

PMID:
19833462
17.

Hydrodynamic delivery protocols.

Rychahou PG, Evers BM.

Methods Mol Biol. 2010;623:189-95. doi: 10.1007/978-1-60761-588-0_12.

PMID:
20217552
18.

VEGF-specific siRNAs modified with 2'-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model.

Chen S, Gao G, Chen W, Lü Q, Tang S, Hua Z, Ye W, Gu D, Wang S, Zhang Y.

Sci China C Life Sci. 2008 Feb;51(2):104-10. doi: 10.1007/s11427-008-0020-1.

PMID:
18239887
19.

STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.

Huang C, Jiang T, Zhu L, Liu J, Cao J, Huang KJ, Qiu ZJ.

Int J Oncol. 2011 Jun;38(6):1637-44. doi: 10.3892/ijo.2011.1000. Epub 2011 Apr 8.

PMID:
21479358
20.

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.

Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T.

Cancer Res. 2004 May 15;64(10):3365-70.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk